News
-
-
-
PRESS RELEASE
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement
Aspire Biopharma announces positive consumer feedback for BUZZ BOMB™, a sublingual pre-workout supplement with fast-acting caffeine delivery technology for athletes and fitness enthusiasts. Plans for product launch at FITCON and Fit Expo conventions in August -
-
-
PRESS RELEASE
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Aspire Biopharma completes Phase 1 trial enrollment for fast-acting high-dose aspirin formulation, expecting topline results in mid Q3 2025 -
-
-
PRESS RELEASE
Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer
Michael Howe to become CEO of Aspire Biopharma Holdings, Inc. on June 10, 2025. His extensive career in leading brands and early-stage companies makes him a strategic fit for the role -
